🦟 From #Mali’s success to #BurkinaFaso’s, our #IMVACS project is moving forward on the #malaria vaccination campaign.
The IMVACs project will build multidisciplinary evidence to support integrating the malaria vaccine with seasonal malaria chemoprevention in West Africa.
The IMVACs project will build multidisciplinary evidence to support integrating the malaria vaccine with seasonal malaria chemoprevention in West Africa.
September 15, 2025 at 8:32 AM
🦟 From #Mali’s success to #BurkinaFaso’s, our #IMVACS project is moving forward on the #malaria vaccination campaign.
The IMVACs project will build multidisciplinary evidence to support integrating the malaria vaccine with seasonal malaria chemoprevention in West Africa.
The IMVACs project will build multidisciplinary evidence to support integrating the malaria vaccine with seasonal malaria chemoprevention in West Africa.
How can we better protect children from malaria in highly seasonal regions?
Epicentre is pleased to be part of the Imvacs Project testing an integrated approach: combining the R21/Matrix-M vaccine with Seasonal Malaria Chemoprevention for children in Mali & Burkina Faso.
youtu.be/r2v9EvWQ1JE?...
Epicentre is pleased to be part of the Imvacs Project testing an integrated approach: combining the R21/Matrix-M vaccine with Seasonal Malaria Chemoprevention for children in Mali & Burkina Faso.
youtu.be/r2v9EvWQ1JE?...
World Children’s Day 2025
YouTube video by IMVACS Project
youtu.be
November 20, 2025 at 1:38 PM
How can we better protect children from malaria in highly seasonal regions?
Epicentre is pleased to be part of the Imvacs Project testing an integrated approach: combining the R21/Matrix-M vaccine with Seasonal Malaria Chemoprevention for children in Mali & Burkina Faso.
youtu.be/r2v9EvWQ1JE?...
Epicentre is pleased to be part of the Imvacs Project testing an integrated approach: combining the R21/Matrix-M vaccine with Seasonal Malaria Chemoprevention for children in Mali & Burkina Faso.
youtu.be/r2v9EvWQ1JE?...
We are looking for a coordinator for the IMVACS study comparing 2 strategies for dispensing the R21/Matrix-M vaccine in Mali and Burkina Faso. This position is based in Niamey, Niger.
If you have a Masters or PhD in Public Health and/or Epidemiology, apply here👇
smrtr.io/pkPZ3
If you have a Masters or PhD in Public Health and/or Epidemiology, apply here👇
smrtr.io/pkPZ3
Coordinateur (trice) Etude « IMVACS » (F/H) CDD 12 mois basé (é) à Niamey, Niger
Description de l'entreprise: Créée par Médecins Sans Frontières (MSF) en 1986, Epicentre mène des activités d’épidémiologie de terrain, de formation et de recherche médicale en appui aux objectifs hum...
smrtr.io
December 20, 2024 at 2:08 PM
We are looking for a coordinator for the IMVACS study comparing 2 strategies for dispensing the R21/Matrix-M vaccine in Mali and Burkina Faso. This position is based in Niamey, Niger.
If you have a Masters or PhD in Public Health and/or Epidemiology, apply here👇
smrtr.io/pkPZ3
If you have a Masters or PhD in Public Health and/or Epidemiology, apply here👇
smrtr.io/pkPZ3
In Mali, an ancillary study compares two R21/Matrix-M vaccine formulation —10-dose vs. 2-dose—to simplify logistics, as part of the broader #IMVACS project which aims to evaluate the effectiveness of a new integrated strategy for administering this vaccine.
www.imvacs.org/safli-r21-10/
www.imvacs.org/safli-r21-10/
SAFLI-R21-10 - IMVACS
SAFLI-R21-10 SAFLI-R21-10 is an ancillary study conducted within the framework of the broader IMVACS project but under a stand-alone protocol separate from the main IMVACS study. This study is designe...
www.imvacs.org
October 28, 2025 at 11:37 AM
In Mali, an ancillary study compares two R21/Matrix-M vaccine formulation —10-dose vs. 2-dose—to simplify logistics, as part of the broader #IMVACS project which aims to evaluate the effectiveness of a new integrated strategy for administering this vaccine.
www.imvacs.org/safli-r21-10/
www.imvacs.org/safli-r21-10/
Great to see the IMVACS malaria vaccine trial advancing in Mali!
Epicentre is proud to be part of this important study with local research teams in Mali and Burkina Faso to identify the most effective strategy to protect young children from malaria. www.imvacs.org/official-sta...
Epicentre is proud to be part of this important study with local research teams in Mali and Burkina Faso to identify the most effective strategy to protect young children from malaria. www.imvacs.org/official-sta...
Official start of vaccination in Mali - IMVACS
10th June 2025 marked the official start of vaccination in the control arm of the IMVACS clinical trial in Dioïla district, Mali. Just two days earlier, on June 8th, a shipment of 9,000 doses of the R...
www.imvacs.org
July 7, 2025 at 9:43 AM
Great to see the IMVACS malaria vaccine trial advancing in Mali!
Epicentre is proud to be part of this important study with local research teams in Mali and Burkina Faso to identify the most effective strategy to protect young children from malaria. www.imvacs.org/official-sta...
Epicentre is proud to be part of this important study with local research teams in Mali and Burkina Faso to identify the most effective strategy to protect young children from malaria. www.imvacs.org/official-sta...
🚀 Proud to be part of the IMVACS Consortium, working on an integrated delivery strategy for the R21/Matrix-M Malaria #vaccine! 💉
The recent advances in malaria vaccination bring new hope, but ensuring equitable access and effective delivery is now the key challenge.
www.imvacs.org/imvacs-kick-...
The recent advances in malaria vaccination bring new hope, but ensuring equitable access and effective delivery is now the key challenge.
www.imvacs.org/imvacs-kick-...
IMVACS Kick-off meeting - IMVACS
On 11th and 12th February 2025, the IMVACS Consortium held its Kick-off Meeting at Novotel Marcory, in Abidjan, Côte d'Ivoire. The meeting was opened by Prof. William Yavo, the General Director of the...
www.imvacs.org
March 11, 2025 at 10:45 AM
🚀 Proud to be part of the IMVACS Consortium, working on an integrated delivery strategy for the R21/Matrix-M Malaria #vaccine! 💉
The recent advances in malaria vaccination bring new hope, but ensuring equitable access and effective delivery is now the key challenge.
www.imvacs.org/imvacs-kick-...
The recent advances in malaria vaccination bring new hope, but ensuring equitable access and effective delivery is now the key challenge.
www.imvacs.org/imvacs-kick-...
Peter Hammersmith speaking at #ImVacS on convergence between canonical signaling (RAS, PI3K) and immuno-oncology. #oncology #singularity
December 1, 2024 at 9:52 PM
Peter Hammersmith speaking at #ImVacS on convergence between canonical signaling (RAS, PI3K) and immuno-oncology. #oncology #singularity
Main takehome points of #ImVacS today: Tim-3, Tim-3, Tim-3, and combinations, combinations, combinations. #immunotherapy #oncology
December 1, 2024 at 9:51 PM
Main takehome points of #ImVacS today: Tim-3, Tim-3, Tim-3, and combinations, combinations, combinations. #immunotherapy #oncology
While his point may be salient it is no excuse to be rude to the speaker. He should kvetch to the #imvacs organizers and @CHI_Healthtech
December 1, 2024 at 9:51 PM
While his point may be salient it is no excuse to be rude to the speaker. He should kvetch to the #imvacs organizers and @CHI_Healthtech
At #ImVacS and just heard an academic speaker call out an industry speaker about not disclosing his companies new preclinical targets (1/2)
December 1, 2024 at 9:51 PM
At #ImVacS and just heard an academic speaker call out an industry speaker about not disclosing his companies new preclinical targets (1/2)
Looking forward to being in Boston next week for ImVacS: The Immunotherapies and Vaccine Summit http://goo.gl/fb/O6edCF”
December 1, 2024 at 9:51 PM
Looking forward to being in Boston next week for ImVacS: The Immunotherapies and Vaccine Summit http://goo.gl/fb/O6edCF”